Led · Equity · Sep 2025

Founded in 2020, Scindo has built a proprietary, data-rich platform that combines experimentally validated reaction datasets with advanced AI models to discover, design and optimise novel enzymes. These enzymes catalyse the conversion of challenging, renewable feedstocks directly into bio-active ingredients, offering a sustainable alternative to petroleum-derived chemicals. The company positions its technology as a full-stack solution that enables consistent, scalable production of natural ingredients across multiple high-value sectors such as food, flavourings, cosmetics and specialty chemicals. Industry traction is already evident through partnerships with leading specialty chemical manufacturers and pilot-scale initiatives aimed at bringing the first products to market. Recent hiring from top pharmaceutical firms and the University of Oxford has strengthened expertise in machine learning, enzyme engineering, process scaling and commercialisation. Proceeds from the latest funding will expand the enzyme discovery engine, scale wet-lab capabilities and grow the team. The company did not disclose revenue or user metrics, but investor interest highlights strong demand for bio-based solutions that deliver both performance and sustainability.

Participated · Equity · Sep 2025

Founded in 2019, NxtFood produces plant-based chicken, beef, and pork alternatives made from locally grown wheat and pea proteins. Its 20-plus SKUs are distributed in all major French food retailers and more than 10,000 foodservice outlets, making it one of the country’s fastest-growing alt-meat startups. Revenue rose from €1 million in 2022 to €9.2 million in 2023, and the company expects to reach €17.4 million in 2024. NxtFood operates a high-moisture-extrusion facility in Vitry-en-Artois and plans to triple its footprint to 12,000 m². The fresh capital will also fund additional R&D and accelerate sales and co-manufacturing partnerships across Europe. Management targets profitability within 12–18 months and emphasizes short ingredient lists, balanced nutrition, and clean labels to meet consumer demand.

Participated · Equity · Sep 2024

MiAlgae cultivates microalgae on by-products from whisky distillation to produce sustainable omega-3s for aquafeed, pet food and human health markets. Its NaturAlgae product is positioned as a drop-in omega-3 alternative to reduce reliance on wild fish. The company is based at Heriot-Watt University and launched a demonstrator site in 2023 that validated its technology at scale. MiAlgae is now preparing to develop an industrial-scale production facility in Scotland to fully commercialise NaturAlgae. The business recently secured £14 million in fresh funding to support that scale-up and to help create green jobs. Management says the investment will be used to build the infrastructure needed to meet growing global demand while continuing biotechnology innovation. MiAlgae, founded in 2016 and led by Managing Director Douglas Martin, applies biotechnology to produce a sustainable source of omega-3 for animal and human consumption. The company’s platform uses low-value coproducts from the food and drink industry as a feedstock to grow microalgae rich in omega-3 oils. MiAlgae is initially focused on the pet food sector with planned near-term expansion into aquaculture, the largest global consumer of fish oil. It also intends to commercialise other high-value compounds and pigments through expansion of its platform. The recently raised funds will be used to expand the team and complete a commercial demonstrator facility near Stirling to drive commercial traction. Financially, the company secured a £2.3M funding package from new and returning investors to support these commercialisation efforts. MiAlgae is a biotech company that produces microalgae using co-products from the whisky distillation process. The microalgae are high in omega-3 and other nutrients and can be used to sustainably feed fish and create animal food. The company targets the global aquaculture and pet food industries. MiAlgae plans to use the £1m funding to commercialize its product, double the size of its business premises, commission a demonstrator plant in East Lothian and make five new appointments in the next 12 months. The round was backed by Equity Gap, Scottish Investment Bank, Old College Capital and new investor Hillhouse Group. Founded by Douglas Martin in 2016 and based in Edinburgh, Scotland, the company intends to scale operations to serve international markets. MiAlgae produces a new kind of nutritious animal feed made from microalgae grown using co-products from Scotland’s whisky distillation process. The microalgae is rich in omega-3 and other vital nutrients and is aimed initially at the aquaculture industry. The company says the product is economical and environmentally friendly and can serve as an alternative raw material for agricultural feed. MiAlgae plans to use the new funding to scale and expand production capacity 30-fold, expand its team, and build a new plant at a whisky distillery. The company is led by founder Douglas Martin and is based in Scotland. The article does not report revenue or user metrics.

Participated · Equity · Sep 2024

Abolis Biotechnologies, based in Évry-Courcouronnes, France, specializes in industrial solutions using microorganisms across food, healthcare, cosmetics and chemicals. The company combines expertise in biology, fermentation, IT, robotics, analytics and industrial property to develop bioproduction solutions. It leverages biotechnologies and micro-organisms to create economically and ecologically sustainable alternatives to petrochemical products and chemical ingredients. Abolis raised €35M in funding to support its growth. Backers included L’Oréal’s venture capital fund BOLD, DeepTech & Climate Fonds, and Evonik Venture Capital as lead investors, alongside Clay Capital, ICOS Capital and Liberset. The company intends to use the funds to accelerate expansion into global markets and to speed R&D to bring its own portfolio of ingredients, to be industrialized with partners, to market. The investment was accompanied by a new strategic industrial partnership between Abolis, L’Oréal and Evonik to bring selected innovations to market for the healthcare, cosmetic and chemical sectors. The company is led by CEO Cyrille Pauthenier.

Participated · Series A · Feb 2024

WeedOUT, based in Ness Ziona, Israel, provides a green solution for outsmarting resistant weeds using a proprietary weed pollen derived from male plants. Its sterile pollen fertilizes female weed ovules to yield nonviable seeds, impeding the growth of new generations of resistant weeds while supporting improved yields and reduced herbicide need. The company is moving to launch its inaugural product targeting Palmer amaranth (Amaranthus palmeri), a major nuisance in the United States, Brazil, and Argentina. It plans to expand field trials in multiple U.S. regions, including Georgia and Nebraska, and is developing new formulations targeting different weed species. WeedOUT recently submitted a request to the U.S. Environmental Protection Agency for marketing approval. The company is led by Co-CEOs Efrat Lidor Nili and Dr. Orly Noivirt-Brik and recently raised $8.1M in Series A funding. Founded in 2016 in Israel, WeedOUT develops biological herbicides that imitate pollen so they can be applied while weeds are flowering to overcome herbicide resistance. Its platform uses the weeds' natural reproductive system; the first product specifically targets Palmer's amaranth, a glyphosate-resistant threat to cotton and soybean. The company is targeting North America as its first commercialization market and sought North American expertise from investors. Fulcrum Global Capital highlighted an investor base representing more than 500,000 acres of row crop producers and its partner Kevin Lockett joined WeedOUT's board. Co-founders Efrat Lidor Nili and Orly Noivirt-Brik previously worked at Monsanto's Israel unit after Rosetta Green was acquired. The Series A funds will be used for product development, scaling operations, and regulatory advancements. WeedOUT produces a green bioherbicide that artificially pollinates target weeds with proprietary weed pollen to induce seed abortion and prevent germination. The technology aims to stop the next generation of weeds and reduce reliance on higher chemical doses against resistant weeds. Its bioherbicide is described as non-toxic and non-invasive to crops. WeedOUT was named Best Israeli Agtech Company in the 2018 AgriVest Competition and was later selected as the winner of the Radicle Challenge Israel. As Challenge winner the company received a $250,000 award and access to Radicle Growth’s custom acceleration program, venture partners, and strategic alliances. WeedOUT plans to use the funding and acceleration support to expedite product development, manufacturing scale-up, and build on the success of field trials.